The decision to use this mouse model was based on the known effects of RELN signaling on Tau phosphorylation24 and our clinical observations of a relative reduction of tauopathy in certain brain regions from postmortem human brain samples of the protected case. The gene discussed is MAPT; the disease is tauopathy.